苑东生物：HP-001胶囊联合地塞米松I/II期临床试验完成首例受试者给药

Core Viewpoint - The announcement highlights the initiation of a Phase I/II clinical trial for HP-001 capsules, a novel oral CRBN-based molecular degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma patients [1] Group 1: Product Development - HP-001 capsules are a new type of oral CRBN-based molecular degrader designed to selectively recruit and degrade transcription factors IKZF1/3, thereby activating anti-tumor responses [1] - Preclinical studies indicate that HP-001 capsules demonstrate superior degradation efficacy and selectivity compared to approved IMiDs and next-generation candidates, with a higher affinity for CRBN [1] Group 2: Clinical Trial Progress - The first subject has been dosed in the clinical trial, marking a significant milestone in the development of HP-001 capsules [1] - The trial aims to evaluate the safety and efficacy of HP-001 in overcoming resistance mechanisms while minimizing on-target and off-target toxicity [1]